RT @SVRaoMD: A great paper on HFrEF and medication titration by @DukeHeartCenter and @DCRINews FIT @SJGreene_md https://t.co/RFt35IjHMl
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @SVRaoMD: A great paper on HFrEF and medication titration by @DukeHeartCenter and @DCRINews FIT @SJGreene_md https://t.co/RFt35IjHMl
RT @AndreasGevaert: We have to rethink our way of prescribing #GDMT in #HeartFailure. In the graph below, only green & yellow pts are recei…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
It is time to Pharmacist run HF titration clinic
RT @bamardis: <1% of HFrEF patients in CHAMP-HF registry on goal BB, RAAS inhibition, and MRA - potential role for #pharmacist-run titratio…
Registry data doesn’t capture maximum tolerated doses, setbacks or slow titrations to mitigate side effects to get on GDMT. Curious to know how many clinics had a pharmacist on their team. HF clinics w/ PharmDs 📉 readmissions, 📈 GDMT targets, and 📈 QOL.
RT @AndreasGevaert: We have to rethink our way of prescribing #GDMT in #HeartFailure. In the graph below, only green & yellow pts are recei…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
Fascinating work @JavedButler1 and colleagues @JACCJournals. Only 11% ACE/ARB use at baseline and only 7% of them uptitrated! I'd be intrigued to see Australian data, and learn from any successful quality improvement efforts internationally @heartfoundatio
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction https://t.co/TfbfLh4MCS
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @AndreasGevaert: We have to rethink our way of prescribing #GDMT in #HeartFailure. In the graph below, only green & yellow pts are recei…
We have to rethink our way of prescribing #GDMT in #HeartFailure. In the graph below, only green & yellow pts are receiving okay drug doses. <1% is on target dose of all drugs. Most start low dose and never get uptitrated. https://t.co/0aoOOlmP6y @J
RT @rcstarling: Thanks for your leadership Gregg. @HFSA is fully supportive and this is an opportunity for HFSA. We accept the challenge!@r…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
Absolutely agree! Isn’t lipid lowering in the same situation at this very time? Brand new biologics, new strategies and interventions in the lab, The Time is Now!
<1% of HFrEF patients in CHAMP-HF registry on goal BB, RAAS inhibition, and MRA - potential role for #pharmacist-run titration clinics? @ATRIUMRx @accpcardprn @HFSA #heartfailure
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SVRaoMD: A great paper on HFrEF and medication titration by @DukeHeartCenter and @DCRINews FIT @SJGreene_md https://t.co/RFt35IjHMl
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SVRaoMD: A great paper on HFrEF and medication titration by @DukeHeartCenter and @DCRINews FIT @SJGreene_md https://t.co/RFt35IjHMl
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SVRaoMD: A great paper on HFrEF and medication titration by @DukeHeartCenter and @DCRINews FIT @SJGreene_md https://t.co/RFt35IjHMl
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
A great paper on HFrEF and medication titration by @DukeHeartCenter and @DCRINews FIT @SJGreene_md https://t.co/RFt35IjHMl
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @rcstarling: Thanks for your leadership Gregg. @HFSA is fully supportive and this is an opportunity for HFSA. We accept the challenge!@r…
RT @drstephenpettit: There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem. https://t.co/kHx…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @pnatarajanmd: Relatively very few patients with HFrEF are receiving goal doses of HF medical therapies https://t.co/ZbGmJBP2xR @JACCJou…
Relatively very few patients with HFrEF are receiving goal doses of HF medical therapies https://t.co/ZbGmJBP2xR @JACCJournals
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
There are similar problems in 🇬🇧. I think specialist HF nurses are the key to unlocking this problem.
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @rcstarling: Thanks for your leadership Gregg. @HFSA is fully supportive and this is an opportunity for HFSA. We accept the challenge!@r…
Thanks for your leadership Gregg. @HFSA is fully supportive and this is an opportunity for HFSA. We accept the challenge!@rcstarling
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
Pharmacists can help! #ACCCVT
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @gcfmd: Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medica…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
Overcoming clinical inertia in HF care will require active intervention and new strategies. The time is now! Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction https://t.co/ypt6P0iWCh @HFSA @rcstarling @JJheart_doc @NMHheartdoc @
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
RT @SJGreene_md: Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low…
Over 1yr of outpatient care, most HFrEF pts have no improvement in GDMT. Most eligible US pts remain on no therapy or low doses. We must address clinical inertia/other barriers to GDMT. Critical opportunity to improve HFrEF outcomes. @JACCJournals https
RT @SJGreene_md: In current US practice, major gaps in outpatient titration of HFrEF medical therapy. Few eligible pts ever receive target…
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…
RT @DrRaniKhatib: Uptitration of Heart Failure medicines. https://t.co/0p6qE3zQw7
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
RT @RomitB_MD: Yikes! And I’m certain this is true in the CV clinics as well. A point well made by mentor @JJheart_doc during our morning r…
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
RT @JACCJournals: At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death…
At #ACC19, Dr. Jukema presents ODYSSEY OUTCOMES that #polyvascular disease is associated with high risk of MACE and death in pts with ACS and dyslipidemia. #PCSK9 showed large reduction in these risks. Full study in #JACC: https://t.co/fXNG5BIIN8 @gabriels
RT @JACCJournals: Majority of eligible #HFrEF pts don't receive target doses of med. therapy at any point. In an #ACC19 poster, published i…